Two Sigma Advisers’s Theravance Biopharma TBPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $321K | Buy |
29,100
+4,400
| +18% | +$48.5K | ﹤0.01% | 1931 |
|
|
2025
Q1 | $221K | Buy |
+24,700
| New | +$221K | ﹤0.01% | 2108 |
|
|
2024
Q3 | – | Sell |
-33,900
| Closed | -$287K | – | 2521 |
|
|
2024
Q2 | $287K | Buy |
+33,900
| New | +$287K | ﹤0.01% | 2085 |
|
|
2023
Q3 | – | Sell |
-94,300
| Closed | -$976K | – | 2571 |
|
|
2023
Q2 | $976K | Sell |
94,300
-389,500
| -81% | -$4.03M | ﹤0.01% | 1542 |
|
|
2023
Q1 | $5.25M | Sell |
483,800
-524,800
| -52% | -$5.69M | 0.01% | 787 |
|
|
2022
Q4 | $11.3M | Buy |
1,008,600
+312,000
| +45% | +$3.5M | 0.03% | 480 |
|
|
2022
Q3 | $7.06M | Buy |
+696,600
| New | +$7.06M | 0.02% | 602 |
|
|
2022
Q2 | – | Sell |
-10,700
| Closed | -$102K | – | 2866 |
|
|
2022
Q1 | $102K | Buy |
+10,700
| New | +$102K | ﹤0.01% | 2503 |
|
|
2021
Q2 | – | Sell |
-29,800
| Closed | -$608K | – | 2688 |
|
|
2021
Q1 | $608K | Sell |
29,800
-7,200
| -19% | -$147K | ﹤0.01% | 1926 |
|
|
2020
Q4 | $657K | Sell |
37,000
-42,800
| -54% | -$760K | ﹤0.01% | 1757 |
|
|
2020
Q3 | $1.18M | Buy |
79,800
+28,400
| +55% | +$420K | ﹤0.01% | 1431 |
|
|
2020
Q2 | $1.08M | Buy |
+51,400
| New | +$1.08M | ﹤0.01% | 1546 |
|
|
2016
Q4 | – | Sell |
-6,200
| Closed | -$225K | – | 2451 |
|
|
2016
Q3 | $225K | Buy |
+6,200
| New | +$225K | ﹤0.01% | 1996 |
|